Astellas Pharma Inc. (4503.T) JPX

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Naoki Okamura	President, Chief Executive Officer & Director	428M	1962
Katsuyoshi Sugita	Executive Vice President, Chief People Officer & Representative Director	211M	1967
Yoshitsugu Shitaka	Chief Scientific Officer & Senior Managing Executive Officer	0	N/A
Nori Kuwahara	Senior Vice President of Planning & Administration	0	N/A
Nobuaki Tanaka	President of Japan Commercial & Senior Corporate Executive	0	N/A
Tatjana Dragovic	General Counsel, Chief Ethics & Compliance Officer	0	N/A
Jun Kono	Senior Executive Officer & Head of Japan Commercial	0	N/A
Leticia Delgado-Herrera	Vice President and Rx+ M&D Head	0	N/A
Nobuko Kato	Chief Communications & Investor Relations Officer	0	N/A
Nobue Yasuda	General Manager of Finance & Accounting Department	0	N/A
Atsushi Kitamura	Senior Executive Officer & Chief Financial Officer	0	N/A

Name

Title

Pay

Year Born

Naoki Okamura

President, Chief Executive Officer & Director

428M

1962

Katsuyoshi Sugita

Executive Vice President, Chief People Officer & Representative Director

211M

1967

Yoshitsugu Shitaka

Chief Scientific Officer & Senior Managing Executive Officer

N/A

Nori Kuwahara

Senior Vice President of Planning & Administration

N/A

Nobuaki Tanaka

President of Japan Commercial & Senior Corporate Executive

N/A

Tatjana Dragovic

General Counsel, Chief Ethics & Compliance Officer

N/A

Jun Kono

Senior Executive Officer & Head of Japan Commercial

N/A

Leticia Delgado-Herrera

Vice President and Rx+ M&D Head

N/A

Nobuko Kato

Chief Communications & Investor Relations Officer

N/A

Nobue Yasuda

General Manager of Finance & Accounting Department

N/A

Atsushi Kitamura

Senior Executive Officer & Chief Financial Officer

N/A

Description

Astellas Pharma Inc., a venerable Japanese pharmaceutical enterprise established in 1923 and headquartered in Tokyo, operates globally in the research, development, manufacturing, and commercialization of a diverse range of medications. Its extensive product lineup addresses critical health needs, including various oncology treatments such as XTANDI for prostate cancer, XOSPATA, an FLT3 inhibitor for specific relapsed or refractory acute myeloid leukemia, and PADCEV for advanced urothelial cancer. For urological conditions, Astellas offers Betanis/Myrbetriq/BETMIGA to manage symptoms of overactive bladder, mirabegron for neurogenic detrusor overactivity in children, and Vesicare for OAB. Other notable pharmaceuticals include Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, Evrenzo for anemia associated with chronic kidney disease, and the immunosuppressants Prograf/Advagraf/Graceptor/ASTAGRAF, vital for preventing organ transplant rejection. The company also markets Funguard/MYCAMINE, an antifungal agent. Astellas actively fosters innovation through numerous strategic collaborations and partnerships. These include clinical trial agreements with pharmaceutical giants like Merck & Co., Inc. and CytomX Therapeutics, Inc. Demonstrating a broader approach to health, they collaborate with BANDAI NAMCO Entertainment Inc. on developing a smartphone exercise support application. In the realm of scientific discovery, Astellas maintains a research alliance with Harvard University for joint therapeutic and technological advancements. Further research initiatives involve Actinium Pharmaceuticals, Inc. to advance targeted radiotherapies leveraging their Antibody Warhead Enabling platform, an agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694, and a collaboration with Cytokinetics, Incorporated. A significant strategic alliance and license agreement exist with Minovia Therapeutics Ltd. to research, develop, and commercialize cell therapies for mitochondrial dysfunction.